References
- Marecos C, Ng J, Kurian MA. What is new for monoamine neurotransmitter disorders? J Inherit Metab Dis. 2014;37:619–626.
- Mulvihill KG. Presynaptic regulation of dopamine release: role of the DAT and VMAT2 transporters. Neurochem Int. 2019;122:94–105.
- Chen MK, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease. J Neurochem. 2008;105:78–90.
- Henke A, Kovalyova Y, Dunn M, et al. Toward serotonin fluorescent false neurotransmitters: development of fluorescent dual serotonin and vesicular monoamine transporter substrates for visualizing serotonin neurons. ACS Chem Neurosci. 2018;9:925–934.
- Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368:543–550.
- Jacobsen JC, Wilson C, Cunningham V, et al. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J Inherit Metab Dis. 2016;39:305–308.
- Rath M, Korenke GC, Najm J, et al. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease. J Neurol Sci. 2017;379:296–297.
- Partridge AW, Therien AG, Deber CM. Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease. Proteins. 2004;54:648–656.
- Cordes FS, Bright JN, Sansom MS. Proline-induced distortions of transmembrane helices. J Mol Biol. 2002;323:951–960.
- Ng J, Heales SJ, Kurian MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatr Drugs. 2014;16:275–291.